In myelodysplastic syndrome-derived acute myeloid leukemia cells, CBP/p300 promote the expression of genes important for protein synthesis, and the CBP/p300 HAT inhibitor A-485 and the CBP/p300 bromodomain inhibitor CCS1477 synergize with azacytidine to induce myelodysplastic syndrome-derived leukemia cell death by synergistically suppressing global protein synthesis 76. Here, EP300 is linked to acute myeloid leukemia.